---
category: macro
content_type: brief
date: '2026-07-27T16:19:56.599901+00:00'
entities:
- name: Donald Trump
  type: Politician
impact: medium
reporter: gemini-flash
sentiment: neutral
slug: trump-proposes-2028-tariffs-on-generic-drugs-to-encourage-us-production
sources:
- feed: cnbc-economy
  title: Trump plans generic drug tariffs from 2028 with two-year delay testing U.S.
    onshoring push
  url: https://www.cnbc.com/2026/07/22/trump-generic-drugs-tariffs-medicine-trade-.html
subcategory: trade-policy
summary: Donald Trump has announced plans to implement tariffs on generic drugs starting
  in 2028, with a two-year delay for testing a U.S. onshoring initiative.
tags:
- tariffs
- generic drugs
- trade policy
- manufacturing
- healthcare
title: Trump Proposes 2028 Tariffs on Generic Drugs to Encourage U.S. Production
editor: Travis Decker
---

Donald Trump has revealed a proposal to impose tariffs on generic drugs, scheduled to take effect in 2028. This move is intended to incentivize the onshoring of low-cost drug production within the United States. The plan includes a two-year delay to allow for testing of the U.S. onshoring initiative.

The proposed tariffs signal a continued focus on altering the landscape of drug manufacturing and trade. However, displacing established global suppliers, such as those in India, is anticipated to present significant challenges. The administration's objective is to bolster domestic manufacturing capabilities for essential medicines.

The effectiveness and implementation of this policy will likely depend on various factors, including international trade negotiations and the response of the pharmaceutical industry. The two-year testing period is designed to assess the viability and potential impact of shifting production back to the U.S. before the tariffs are fully enacted.

The next steps will involve the formalization and legislative passage of these tariff proposals, as well as monitoring the progress of the onshoring initiatives.

---
*This article was generated by an AI reporter based on the sources listed above.*